Effect of Glucagon on Hepatic Circulation in the Pig

Lindberg, B

doi:10.1001/archsurg.1976.01360300069011

Cited by 12 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of glucagon on hepatic circulation has been revealed in various species (14)(15)(16)(17)(18)(19)(20). Numerous investi-gations have shown that administration of glucagon increased the total liver blood flow in all species examined.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Distribution of Glucagon, Substance P and Vasoactive Intestinal Polypeptide in Hepatic Vasculature of the Rat

et al. 1984

View full text Add to dashboard Cite

The distribution of immunoreactive glucagon, substance P (SP) and vasoactive intestinal polypeptide (VIP)-like structures was investigated in the rat liver, with special reference to the hepatic vasculature by means of the indirect immunofluorescence method. Immunoreactive structures of glucagon were seen in the walls of the portal vein, hepatic artery and hepatic vein, but not in the central vein. Immunoreactive glucagon was localized in the smooth muscle cells of these blood vessels. SP and VIP-like immunoreactive (SPI and VIPI) structures were seen in the neuronal elements. In the porta hepatis, thick, compact SPI and VIPI fibers, which were dissociated from their fiber bundles, reached the tunica adventitia where they were distributed. No SPI and VIPI structures were seen in the tunica media or the tunica interna. No SPI- and VIPI-containing cell bodies could be detected in the liver. These observations suggest that these peptides may have an important role in the neural regulation of hepatic hemodynamics.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Distribution of Glucagon, Substance P and Vasoactive Intestinal Polypeptide in Hepatic Vasculature of the Rat

et al. 1984

View full text Add to dashboard Cite

show abstract

“…However, the aMSA pig model lacks a tumor, and limitations in this model were previously encountered with respect to dose administration of LIP (≤0.9 mg LIP/kg) when LIP was administered via the HA . Furthermore the blood flow in VP is 2.4-fold increased compared to HA and the VP contributes with 66% of the total liver blood supply. − As a higher dose and high hepatic exposure were needed, the VP was used as the administration site for both LIP and CsA, rather than the HA.…”

Section: Methodsmentioning

confidence: 99%

The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs

et al. 2014

View full text Add to dashboard Cite

Doxorubicin (DOX) emulsified in Lipiodol (LIP) is used as local palliative treatment for unresectable intermediate stage hepatocellular carcinoma. The objective of this study was to examine the poorly understood effects of the main excipient in the drug delivery system, LIP, alone or together with cyclosporin A (CsA), on the in vivo liver disposition of DOX and its active metabolite doxorubicinol (DOXol). The advanced, multi-sampling-site, acute pig model was used; samples were collected from three blood vessels (v. portae, v. hepatica and v. femoralis), bile and urine. The four treatment groups (TI-TIV) all received two intravenous 5 min infusions of DOX into an ear vein: at 0 and 200 min. Before the second dose, the pigs received a portal vein infusion of saline (TI), LIP (TII), CsA (TIII) or LIP and CsA (TIV). Concentrations of DOX and DOXol were analyzed using UPLC-MS/MS. The developed multicompartment model described the distribution of DOX and DOXol in plasma, bile and urine. LIP did not affect the pharmacokinetics of DOX or DOXol. CsA (TIII and TIV) had no effect on the plasma pharmacokinetics of DOX, but a 2-fold increase in exposure to DOXol and a significant decrease in hepatobiliary clearance of DOX and DOXol were observed. Model simulations supported that CsA inhibits 99% of canalicular biliary secretion of both DOX and DOXol, but does not affect the metabolism of DOX to DOXol. In conclusion, LIP did not directly interact with transporters, enzymes and/or biological membranes important for the hepatobiliary disposition of DOX.

show abstract

Spasmolytic Action and Clinical Use of Glucagon

Diamant¹,

Picazo²

1983

Glucagon II

View full text Add to dashboard Cite

Effect of Glucagon on Hepatic Circulation in the Pig

Cited by 12 publications

References 14 publications

Immunohistochemical Distribution of Glucagon, Substance P and Vasoactive Intestinal Polypeptide in Hepatic Vasculature of the Rat

Immunohistochemical Distribution of Glucagon, Substance P and Vasoactive Intestinal Polypeptide in Hepatic Vasculature of the Rat

The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs

Spasmolytic Action and Clinical Use of Glucagon

Contact Info

Product

Resources

About